Researchers are developing a targeted therapy that could change the outlook for patients with one of the most aggressive forms of breast cancer. A new federally funded project aims to deliver chemotherapy directly to tumor cells in triple negative breast cancer, a subtype that currently has few effective treatment options.
Triple negative breast cancer accounts for 10 to 15 percent of all breast cancer cases and is associated with higher recurrence rates and poorer outcomes than other subtypes. Unlike other breast cancers, it lacks the estrogen, progesterone, and HER2 receptors that most existing therapies target. The disease disproportionately affects younger women, premenopausal African American and Hispanic women, and those from lower socioeconomic backgrounds.
The research focuses on novel peptide drug conjugates designed to recognize and bind to EGFR, a protein found in elevated levels on the surface of triple negative breast cancer cells. By delivering chemotherapy drugs directly to these cells, the approach aims to dramatically increase drug concentration at the tumor site while sparing healthy tissue. The team reports that this method can deliver several fold higher levels of drug to cancer cells compared with giving the drug alone.
How the Targeted Delivery Works
Targeted drug delivery has transformed cancer treatment by directing cancer killing drugs more precisely to tumor cells. In this project, the peptide drug conjugates act like guided missiles. They seek out EGFR receptors on cancer cells, bind to them, and release the chemotherapy payload directly inside the tumor. This precision reduces the collateral damage to healthy cells that often causes harsh side effects in standard chemotherapy.
The research team brings together expertise in medicinal chemistry, cancer biology, and drug delivery. The project leader has more than 25 years of experience in medicinal chemistry and directs a center focused on targeted drug delivery. The team plans to test the conjugates in preclinical models to determine the most effective formulations before moving toward human trials.
If successful, this approach could offer a new lifeline for patients with triple negative breast cancer who currently face limited options. The researchers are optimistic that the peptide drug conjugates could eventually be combined with existing treatments to improve outcomes and reduce side effects. The next steps involve refining the drug design and moving through the regulatory pipeline toward clinical testing. For the millions of women affected by this aggressive cancer, the work represents a promising step forward.